Effectiveness and safety of daily versus alternate-day rosuvastatin dose in dyslipidemic patients: a prospective, randomized and open-label study

Simple item page
dc.contributor.authorDafda, Aen_US
dc.contributor.authorSingh, NRen_US
dc.contributor.authorChhabra, Aen_US
dc.date.accessioned2025-06-18T11:23:12Z
dc.date.available2025-06-18T11:23:12Z
dc.date.issued2025-02
dc.description.abstractBackground: Dyslipidemia is considered to be an important risk factor for development of atherosclerotic cardiovascular disease (ASCVD). Statins, also called HMG CoA reductase inhibitors are considered to the most effective lipid lowering agents. This study assessed the effectiveness and safety of daily versus alternate day dosing regimens of rosuvastatin in dyslipidemia patients. Methods: This study was conducted for a period of 12 weeks. Study subjects comprised patients of either sex in age group 18-65 years diagnosed with dyslipidemia and a total of 90 subjects completed study who were randomly distributed to three groups, A (rosuvastatin 10 mg daily), B (rosuvastatin 10 mg on alternate days) and C (rosuvastatin 20 mg on alternate days). Results: Rosuvastain significantly lowered total cholesterol, low density lipoprotein-cholesterol and triglycerides in all groups (p<0.001). High density lipoprotein-cholesterol increased, but non-significantly (p>0.05). Intergroup differences were not statistically significant. Group A reported slightly more adverse events than group B and group C. Conclusions: Alternate-day rosuvastatin therapy showed effectiveness statistically similar to the daily dose therapy in dyslipidemic individuals. It also exhibited fewer side effects, suggesting it could be a feasible approach for managing dyslipidemia, providing a more economical and potentially safer alternative to daily administration.en_US
dc.identifier.affiliationsDepartment of Pharmacology, Government Medical College, Amritsar, Punjab, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacology, Government Medical College, Amritsar, Punjab, Indiaen_US
dc.identifier.affiliationsDepartment of Medicine, Government Medical College, Amritsar, Punjab, Indiaen_US
dc.identifier.citationDafda A, Singh NR, Chhabra A. Effectiveness and safety of daily versus alternate-day rosuvastatin dose in dyslipidemic patients: a prospective, randomized and open-label study. International Journal of Basic & Clinical Pharmacology. 2025 Feb; 14(1): 50-54en_US
dc.identifier.issn2319-2003
dc.identifier.issn2279-0780
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/248653
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber1en_US
dc.relation.volume14en_US
dc.source.urihttps://doi.org/10.18203/2319-2003.ijbcp20243835en_US
dc.subjectDyslipidemiaen_US
dc.subjectStatinsen_US
dc.subjectRosuvastatinen_US
dc.subjectLipid profileen_US
dc.titleEffectiveness and safety of daily versus alternate-day rosuvastatin dose in dyslipidemic patients: a prospective, randomized and open-label studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijbcp2025v14n1p50.pdf
Size:
167.3 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Basic & Clinical Pharmacology